Abstracts tagged "Biologic drugs and rheumatoid arthritis"

Abstract Number: 520 • 2017 ACR/ARHP Annual Meeting
Clinical and Structural Responses of Patients with Active Rheumatoid Arthritis (RA) Using Step-up Dosing of Tofacitinib in a Treat to Target Approach
Norman Gaylis¹, Joanne Sagliani¹ and Steven Needell², ¹Arthritis & Rheumatic Disease Specialties, Aventura, FL, ²Boca Radiology, Boca Raton, FL
Background/Purpose: Tofacitinib has been shown to reduce the clinical signs and symptoms of some RA patients at an approved dose of 5 mg bid. Studies…
Abstract Number: 1432 • 2017 ACR/ARHP Annual Meeting
The Prognostic Value of IgA Subtypes of Rheumatoid Factor and Anti-Citrullinated Protein Antibodies (ACPA) for Prediction of Therapeutic Responses to TNF Inhibitory Therapy in Patients with Rheumatoid Arthritis
Daniela Sieghart¹, Farideh Alasti², Paul Studenic¹ and Günter Steiner², ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid factor (RF) and Anti-Citrullinated Protein antibodies (ACPA) are the most specific diagnostic markers of rheumatoid arthritis (RA). These antibodies are predominantly of the…